Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the ...
Submissions are supported by data from the Phase 3 Viti-Up clinical studies demonstrating upadacitinib achieved the co-primary endpoints of at least a 50% improvement ...
A machine learning model incorporating functional assessments predicts one-year mortality in older patients with HF and improves risk stratification beyond established scores. Functional status at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results